Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity nudges up target price on Celtic

(Sharecast News) - Analysts at Canaccord Genuity slightly raised their target price on Celtic from 202.0p to 208.0p on Tuesday, stating the firm's improved UCL campaign drives FY25 upgrades. Canaccord Genuity said Celtic has continued to make strong progress across the first half of FY25, with a "strong start" to the 2024/25 league season being complemented by the winning of the Scottish League Cup and a successful UCL League stage campaign.

"After two years of disappointing UCL Group stage campaigns, the Club has seen a marked improvement in Europe's elite club competition and has successfully qualified for the knock-out stages of the competition for the first time since 2013," said Canaccord. "We believe the Club remains well positioned for further success this season, with a commanding lead in the SPFL after winning a third successive league title in 2023/24, making it 12 titles out of the previous 13."

The Canadian bank also noted that the change to the UCL format, with games now played in the Club's second half, and a change in the composition of home matches played, have resulted in a small re-profiling of group revenues into H225, whilst higher wages and stadium investment has seen reduced H125 profit pre-player trading.

"We have increased our FY25E forecasts to reflect the improved UCL campaign, albeit the full FY25 outcome clearly remains contingent on results across the remainder of the season," concluded the analysts, who reiterated their 'buy' rating on the stock.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.